These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 19775995)

  • 41. Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma.
    Han LY; Landen CN; Kamat AA; Lopez A; Bender DP; Mueller P; Schmandt R; Gershenson DM; Sood AK
    J Clin Oncol; 2006 Feb; 24(5):755-61. PubMed ID: 16380413
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Angiogenesis in epithelian ovarian cancer.
    Bamberger ES; Perrett CW
    Mol Pathol; 2002 Dec; 55(6):348-59. PubMed ID: 12456770
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expression of hypoxia-inducible factor 1alpha gene affects the outcome in patients with ovarian cancer.
    Shimogai R; Kigawa J; Itamochi H; Iba T; Kanamori Y; Oishi T; Shimada M; Sato S; Kawaguchi W; Sato S; Terakawa N
    Int J Gynecol Cancer; 2008; 18(3):499-505. PubMed ID: 18476949
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Potent inhibition of tumoral hypoxia-inducible factor 1alpha by albendazole.
    Pourgholami MH; Cai ZY; Badar S; Wangoo K; Poruchynsky MS; Morris DL
    BMC Cancer; 2010 Apr; 10():143. PubMed ID: 20398289
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Migration-inducing gene 7 promotes tumorigenesis and angiogenesis and independently predicts poor prognosis of epithelial ovarian cancer.
    Huang B; Yin M; Li X; Cao G; Qi J; Lou G; Sheng S; Kou J; Chen K; Yu B
    Oncotarget; 2016 May; 7(19):27552-66. PubMed ID: 27050277
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma.
    Osada R; Horiuchi A; Kikuchi N; Yoshida J; Hayashi A; Ota M; Katsuyama Y; Melillo G; Konishi I
    Hum Pathol; 2007 Sep; 38(9):1310-20. PubMed ID: 17555795
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fibulin-4 is associated with tumor progression and a poor prognosis in ovarian carcinomas.
    Chen J; Liu Z; Fang S; Fang R; Liu X; Zhao Y; Li X; Huang L; Zhang J
    BMC Cancer; 2015 Mar; 15():91. PubMed ID: 25885889
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Erythropoietin disrupts hypoxia-inducible factor signaling in ovarian cancer cells.
    Hale SA; Wong C; Lounsbury KM
    Gynecol Oncol; 2006 Jan; 100(1):14-9. PubMed ID: 16226302
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reactive oxygen species regulate FSH-induced expression of vascular endothelial growth factor via Nrf2 and HIF1α signaling in human epithelial ovarian cancer.
    Zhang Z; Wang Q; Ma J; Yi X; Zhu Y; Xi X; Feng Y; Jin Z
    Oncol Rep; 2013 Apr; 29(4):1429-34. PubMed ID: 23404377
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma.
    Merritt WM; Danes CG; Shahzad MM; Lin YG; Kamat AA; Han LY; Spannuth WA; Nick AM; Mangala LS; Stone RL; Kim HS; Gershenson DM; Jaffe RB; Coleman RL; Chandra J; Sood AK
    Cancer Biol Ther; 2009 Aug; 8(16):1596-603. PubMed ID: 19738426
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinoma.
    Karavasilis V; Malamou-Mitsi V; Briasoulis E; Tsanou E; Kitsou E; Pavlidis N
    Int J Gynecol Cancer; 2006; 16 Suppl 1():241-6. PubMed ID: 16515598
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Down-modulation of TNFSF15 in ovarian cancer by VEGF and MCP-1 is a pre-requisite for tumor neovascularization.
    Deng W; Gu X; Lu Y; Gu C; Zheng Y; Zhang Z; Chen L; Yao Z; Li LY
    Angiogenesis; 2012 Mar; 15(1):71-85. PubMed ID: 22210436
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of the antiangiogenic effect of Taxol in a human epithelial ovarian carcinoma cell line.
    Hata K; Osaki M; Dhar DK; Nakayama K; Fujiwaki R; Ito H; Nagasue N; Miyazaki K
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):68-74. PubMed ID: 14569416
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).
    Ruscito I; Cacsire Castillo-Tong D; Vergote I; Ignat I; Stanske M; Vanderstichele A; Glajzer J; Kulbe H; Trillsch F; Mustea A; Kreuzinger C; Benedetti Panici P; Gourley C; Gabra H; Nuti M; Taube ET; Kessler M; Sehouli J; Darb-Esfahani S; Braicu EI
    Br J Cancer; 2018 Aug; 119(3):330-338. PubMed ID: 29955134
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tissue inhibitor of metalloproteinases-3 interacts with angiotensin II type 2 receptor and additively inhibits angiogenesis.
    Kang KH; Park SY; Rho SB; Lee JH
    Cardiovasc Res; 2008 Jul; 79(1):150-60. PubMed ID: 18344519
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of hypoxia-inducible factor-2 alpha in angiogenesis.
    Befani C; Liakos P
    J Cell Physiol; 2018 Dec; 233(12):9087-9098. PubMed ID: 29968905
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hypoxia-induced changes in the expression of VEGF, HIF-1 alpha and cell cycle-related molecules in ovarian cancer cells.
    Horiuchi A; Imai T; Shimizu M; Oka K; Wang C; Nikaido T; Konishi I
    Anticancer Res; 2002; 22(5):2697-702. PubMed ID: 12529984
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MicroRNA-497 suppresses angiogenesis by targeting vascular endothelial growth factor A through the PI3K/AKT and MAPK/ERK pathways in ovarian cancer.
    Wang W; Ren F; Wu Q; Jiang D; Li H; Shi H
    Oncol Rep; 2014 Nov; 32(5):2127-33. PubMed ID: 25176450
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tumour-associated angiogenesis in human colorectal cancer.
    Rmali KA; Puntis MC; Jiang WG
    Colorectal Dis; 2007 Jan; 9(1):3-14. PubMed ID: 17181841
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
    Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
    Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.